Zhaoke Ophthalmology Limited (HKG:6622)
3.460
0.00 (0.00%)
At close: Feb 13, 2026
Zhaoke Ophthalmology Revenue
Zhaoke Ophthalmology had revenue of 15.80M CNY in the half year ending June 30, 2025, with 39.80% growth. This brings the company's revenue in the last twelve months to 35.36M, down -38.20% year-over-year. In the year 2024, Zhaoke Ophthalmology had annual revenue of 69.32M with 269.73% growth.
Revenue (ttm)
35.36M CNY
Revenue Growth
-38.20%
P/S Ratio
48.94
Revenue / Employee
130.96K CNY
Employees
270
Market Cap
1.90B HKD
Revenue Chart
* This company reports financials in CNY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 69.32M | 50.57M | 269.73% |
| Dec 31, 2023 | 18.75M | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Frontage Holdings | 1.99B |
| Hangzhou Jiuyuan Genetic Biopharmaceutical | 1.43B |
| Mabpharm | 464.53M |
| Cutia Therapeutics | 274.31M |
| ImmuneOnco Biopharmaceuticals (Shanghai) | 134.60M |
| Antengene Corporation | 92.43M |
| CANbridge Pharmaceuticals | 68.55M |
| SinoMab BioScience | 6.28M |